



Aduro Biotech's Stephen T. Isaacs Named 2016 Visionary Leader by Berkeley Chamber of Commerce

September 26, 2016

BERKELEY, Calif., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced that Stephen T. Isaacs, the company's chairman, president and CEO, will receive the Berkeley Chamber of Commerce Visionary Award. One of three recipients for 2016, Mr. Isaacs was recognized for his commitment to innovation and his visionary leadership within the city of Berkeley.

A photo accompanying this announcement is available at <http://www.globenewswire.com/NewsRoom/AttachmentNg/ab2a14fb-8573-416b-989e-484f04910ffb>

"Steve is a consummate innovator and incredible leader," said G. Steven Martin, Ph.D., former dean of Biological Sciences at the University of California in Berkeley. "He is one of few in the industry with the foresight to begin advancing research in immuno-oncology over a decade ago. Additionally, his visionary leadership has forged deep ties between biotech and academia, as well as between the city of Berkeley and countries around the world. A prime example of this is Aduro's research collaboration with U.C. Berkeley through their Immunotherapeutics and Vaccine Research Initiative (IVRI), with the aim of accelerating breakthrough discoveries and making an impact on global health. For his many accomplishments and admirable character, I extend my sincerest congratulations to Steve for this well-deserved award."

The Berkeley Chamber of Commerce created the Visionary Awards to celebrate people with imagination and persistence to innovate in the City of Berkeley. Long known as a city on the vanguard of public policy and social activism, Berkeley is growing its reputation as a place for world-leading companies. These enterprises represent the latest generation of Berkeleyans working to change the world. Their visions are key to the vitality of Berkeley and the greater Bay Area.

With the unique attributes of UC Berkeley, the Berkeley Lab, and the dynamic community, entrepreneurs are choosing Berkeley as the place to launch their ventures. Their companies are striving to meet the challenges of the next generation, while at the same time, creating jobs in the city. The Chamber has partnered with the City of Berkeley, the University of California, and the Lawrence Berkeley National Lab to showcase these leaders.

"We created the Visionary awards to recognize people who are truly making a difference – for our local workforce, for the community and, especially in the case of Steve and Aduro, for people suffering from devastating diseases," commented Kirsten MacDonald, co-chief executive officer of the Berkeley Chamber of Commerce. "We applaud Steve for his persistence in approaching the challenging field of drug development with unique and innovative approaches, for building a thriving biotechnology company, and for identifying revolutionary ways to bring academia and industry together for the benefit of patients not only locally, but also in the developing world."

"It is a tremendous honor to be recognized by the Chamber of Commerce for innovation in this city, which is known for its revolutionary thinking," said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. "For over a decade, we have been in Berkeley working to bring new immunotherapies to patients to transform the treatment of cancer and other challenging diseases. We look forward to our continued commitment to advance immunotherapy – for the benefit of patients, employees and the community."

About Aduro

Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of *Listeria* that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. This platform is being developed as a treatment for multiple indications, including pancreatic, ovarian, lung and prostate cancers, mesothelioma and glioblastoma. Aduro's STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in a Phase 1 study in patients with cutaneously accessible metastatic solid tumors or lymphomas. Aduro's B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit www.aduro.com.



Stephen Isaacs, Aduro Biotech Chairman, President and CEO

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, the potential for our technology platforms, plans, and the potential for eventual regulatory approval of our product candidates. In some cases, you can identify these statements by forward-looking words such as “may,” “will,” “continue,” “anticipate,” “intend,” “could,” “project,” “expect” or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our history of net operating losses and uncertainty regarding our ability to achieve profitability, our ability to develop and commercialize our product candidates, our ability to use and expand our technology platforms to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our inability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, our reliance on third parties, and our ability to obtain and adequately protect intellectual property rights for our product candidates. We discuss many of these risks in greater detail under the heading “Risk Factors” contained in our quarterly report on Form 10-Q for the quarter ended June 30, 2016, which is on file with the Securities and Exchange Commission. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact:

Sylvia Wheeler
SVP, Corporate Affairs
510 809 9264

Media Contact:

Angela Bitting
925 202 6211
press@aduro.com



Aduro Biotech, Inc.